Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab
Doran Ksienski, Elaine S. Wai, Nicole S. Croteau, Ashley Freeman, Angela Chan, Leathia Fiorino, Zia Poonja, David Fenton, Tiffany Patterson, Sarah Irons, Mary Lesperance
Topics & Concepts
MedicinePembrolizumabNivolumabInternal medicineLung cancerCohortPropensity score matchingAdverse effectOdds ratioCancerCohort studyRetrospective cohort studyOncologyImmunotherapyCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Research Studies